Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Non-Aspergillus invasive mold infections (IMIs) are associated with devastating morbidity and mortality rates, and are increasingly diagnosed in immunocompromised hosts. The objective of this study was to describe the epidemiology and outcomes of non-Aspergillus IMIs at our university hospital in San Diego, California, United States. We performed a retrospective chart review of medical records of all patients with cultures growing non-Aspergillus molds at the Microbiology Laboratory in the Center for Academic Laboratory Medicine, Department of Pathology, University of California San Diego (UCSD) Health between mid-2014 and mid-2017 (3 year period). A total of 23 cases of non-Aspergillus IMIs were identified, including 10 cases of mucormycosis, 8 cases of lomentosporiosis, and 5 cases of fusariosis. Antifungal susceptibility testing was performed in 14 isolates and 10/11 Fusarium and Lomentospora isolates had MICs >16 μg/mL for voriconazole and/orposaconazole. Overall 180-day mortality was significantly lower among those who received combination antifungal therapy than among those who received single agent therapy [3/13 (23%) vs. 9/10 (90%); p=0.003]. In conclusion, Lomentospora prolificans (35% of non-Aspergillus IMIs), and Fusarium spp. (22%) accounted for high proportions of non-Aspergillus IMIs during the time period. Non-Aspergillus IMIs were detected in patients with various underlying diseases and associated with high mortality rates, which was significantly lower in those who received antifungal combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Invasive Non- Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006
Park, B. J., Pappas, P. G., Wannemuehler, K. A., Alexander, B. D., Anaissie, E. J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., et al. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110087 · Cited by 321
Cited by
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationHoenigl, M., Salmanton-García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al-Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 470
Self-citationThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“prolificans, where other treatment options are scarce because of pan resistance [2, 4, 176, 177], olorofim may present a “breakthrough” treatment option [151], as it is not only associated with very low MICs but also has antibiofilm activity [178].”
BackgroundSelf-citationThe emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries
Hoenigl, M., Seidel, D., Carvalho, A., Rudramurthy, S. M., Arastehfar, A., Gangneux, J.-P., Nasir, N., Bonifaz, A., Araiza, J., Klimko, N., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00237-8 · Cited by 443
Self-citationEmerging Fungal Infections: New Patients, New Patterns, and New Pathogens
Friedman, D. Z. P., & Schwartz, I. S. (2019) · Journal of Fungi · doi:10.3390/jof5030067 · Cited by 357
Metadata
- Authors
- Jenks, J. D., Reed, S. L., Seidel, D., Koehler, P., Cornely, O. A., Mehta, S. R., & Hoenigl, M.
- Venue
- International Journal of Antimicrobial Agents
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 52
- Issue
- 5
- Pages
- 706-712
- ISSN
- 0924-8579 (ISSN-L)
- OpenAlex
- W2886018149
- Cited by
- 99
- References
- 3
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.